Spots Global Cancer Trial Database for CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Official Title: An Open, Uncontrolled, Multicenter Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of Chimeric Antigen Receptor T Cell (CAR-T) in the Treatment of Relapsed Refractory (R/R) Multiple Myeloma (MM)
Study ID: NCT04626752
Conditions
Study Description
Brief Summary: This study is aimed to evaluate the safety, feasibility and efficacy of CAR-T cell therapy in the treatment of relapsed or refractory multiple myeloma
Detailed Description: This is a study to evaluate the safety, feasibility and efficacy of CAR-T cell therapy in the treatment of relapsed or refractory multiple myeloma. The Main research objectives: To evaluate the safety and efficacy of CAR-T cell therapy in patients with relapsed or refractory multiple myeloma. The Secondary research objectives: To evaluate the safety and efficacy of CAR-T cell therapy in patients with relapsed or refractory multiple myeloma.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
the Second Hospital of HeBei Medical University (HBMU), Shijiazhuang, Hebei, China
Contact Details
Name: Jianmin Luo, PhD&MD
Affiliation: The Second Hospital of Hebei Medical University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
